12:00 AM
 | 
Sep 21, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

rBet v 1: Phase IIb/III data

The double-blind, international Phase IIb/III VO59.08 trial in 483 adult patients showed that 12.5, 25 and 50 µg sublingual tablets of rBet v 1 met the primary endpoint of significantly reducing AASS vs....

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >